Company profile
HUTCHMED (China) Limited logo

HUTCHMED (China) Limited

Pipeline10 assets

  • FruquintinibHMPL-013 / ELUNATE / FRUZAQLA / VEGFR 1/2/3 / Small molecule / Oncology
    Colorectal cancerApproved/MarketedApprovedChinaUSEuropeJapanGastric cancerPhase IIIActiveGlobalOther solid tumors (combination studies)ClinicalActiveGlobal
  • SavolitinibHMPL-504 / AZD6094 / ORPATHYS / c-MET / Small molecule / Oncology
    Non-small cell lung cancer (MET exon 14)Approved/MarketedApprovedChinaNSCLC combinations (with immunotherapy/targeted therapy)Phase IIIActiveGlobal
  • SurufatinibHMPL-012 / SULANDA / VEGFR/FGFR/CSF-1R / Small molecule / Oncology
    Neuroendocrine tumorsApproved/MarketedApprovedChina
  • SovleplenibHMPL-523 / Syk / Small molecule / Hematology/Immunology
    Immune thrombocytopenia (ITP)NDA/Regulatory reviewUnder regulatory reviewChina
  • FanregratinibHMPL-453 / FGFR / Small molecule / Oncology
    Cholangiocarcinoma (FGFR2 fusion)NDA/Regulatory reviewUnder regulatory reviewChina
  • HMPL-760HMPL-760 / BTK (non-covalent) / Small molecule / Oncology/Hematology
    Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)Phase IIIInitiatedChina
  • HMPL-A251HMPL-A251 / HER2 (PI3K/PIKK payload) / Antibody-Targeted Therapy Conjugate (ATTC) / Oncology
    HER2-positive/HER2-low solid tumorsPhase IActiveChinaUS
  • HMPL-A580HMPL-A580 / EGFR (PI3K/PIKK payload) / Antibody-Targeted Therapy Conjugate (ATTC) / Oncology
    Solid tumorsPhase IInitiatedGlobal
  • HMPL-A830HMPL-A830 / ATTC (undisclosed) / Antibody-Targeted Therapy Conjugate (ATTC) / Oncology
    Solid tumorsPreclinical/Phase I plannedPlannedGlobal
  • TazemetostatTAZVERIK / EZH2 / Small molecule / Oncology
    Epithelioid sarcoma / follicular lymphomaLicensed/CommercialLicensed product updateChina

Latest news0 items

All news

No recent headlines yet.

New company coverage will appear here as soon as it is picked up.

HUTCHMED (China) Limited • Endpoint Arena